Actionable Gene Expression-Based Patient Stratification for Molecular Targeted Therapy in Hepatocellular Carcinoma

Background The effectiveness of molecular targeted agents is modest in hepatocellular carcinoma (HCC). Efficacy of molecular targeted therapies has been better in cancer patients with high expression of actionable molecules defined as cognate target molecules. However, patient stratification based on the actionable molecules dictating the effectiveness of targeted drugs has remained understudied in HCC. Experimental Design & Results Paired tumor and non-tumoral tissues derived from a total of 130 HCC patients were studied. Real-time RT-PCR was used to analyze the mRNA expression of actionable molecules in the tissues. mRNA levels of EGFR, VEGFR2, PDGFRβ, FGFR1, and mTOR were up-regulated in tumors compared to non-tumors in 35.4, 42.3, 61.5, 24.6, and 50.0% of patients, respectively. Up-regulation of EGFR was observed at early stage and tended to gradually decrease toward late stages (BCLC stage A: 41.9%; B: 30.8%; C: 17.6%). Frequency of VEGFR2 expression in tumors at stage C was lower than that in the other stages (BCLC stage A: 45.9%; B: 41.0%; C: 29.4%). PDGFRβ and mTOR were observed to be up-regulated in more than 50% of tumors in all the stages whereas FGFR1 was up-regulated in only about 20% of HCC irrespective of stages. A cluster analysis of actionable gene expression revealed that HCC can be categorized into different subtypes that predict the effectiveness of molecular targeted agents and combination therapies in clinical trials. Analysis of in vitro sensitivity to sorafenib demonstrated that HCC cells with up-regulation of PDGFRβ and c-Raf mRNA are more susceptible to sorafenib treatment in a dose and time-dependent manner than cells with low expression of the genes. Conclusions mRNA expression analysis of actionable molecules could provide the rationale for new companion diagnostics-based therapeutic strategies in the treatment of HCC.

[1]  Zhao-You Tang,et al.  Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival , 2009, Journal of Cancer Research and Clinical Oncology.

[2]  X. Wang,et al.  Sixty‐five gene‐based risk score classifier predicts overall survival in hepatocellular carcinoma , 2012, Hepatology.

[3]  B. Evers,et al.  PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. , 2012, The Journal of surgical research.

[4]  Zhiming Wang,et al.  The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma , 2010, Medical oncology.

[5]  D. Carbone,et al.  Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development , 2012, Clinical Cancer Research.

[6]  E. Raymond,et al.  [Targeted therapies in hepatocellular carcinoma]. , 2010, Presse medicale.

[7]  J. Llovet,et al.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. , 2010, Annual review of medicine.

[8]  J. Bruix,et al.  Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects , 2010, Seminars in liver disease.

[9]  Jeff Shrager,et al.  A Novel Classification of Lung Cancer into Molecular Subtypes , 2012, PloS one.

[10]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[11]  S. Maithel,et al.  Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma , 2011, Annals of Surgical Oncology.

[12]  J. Dufour,et al.  Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. , 2012, Journal of hepatology.

[13]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[14]  B. Chauffert,et al.  EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib , 2012, International journal of cancer.

[15]  S. Kakar,et al.  Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. , 2008, American journal of clinical pathology.

[16]  C. Desbois-Mouthon,et al.  Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. , 2012, Journal of hepatology.

[17]  S. Arii,et al.  Molecularly targeted therapy for hepatocellular carcinoma , 2009, Cancer science.

[18]  A. Ryan,et al.  Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines , 2009, Molecular Cancer Therapeutics.

[19]  Sun Young Park,et al.  Imag Ove with Hep , 2010 .

[20]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[21]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Lewis R. Roberts,et al.  Hepatocellular carcinoma: a global view , 2010, Nature Reviews Gastroenterology &Hepatology.

[23]  Derek Y. Chiang,et al.  Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. , 2009, Journal of hepatology.

[24]  Zhao-You Tang,et al.  Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.

[25]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[26]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[27]  Armin Koch,et al.  Personalized medicine using DNA biomarkers: a review , 2012, Human Genetics.

[28]  J. Zucman‐Rossi,et al.  Genetics of Hepatobiliary Carcinogenesis , 2011, Seminars in liver disease.

[29]  J. Llovet,et al.  Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib , 2012, Clinical Cancer Research.

[30]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[31]  B. Conley,et al.  Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use , 2012, Clinical Cancer Research.

[32]  R. Swann,et al.  Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers , 2010, Clinical Cancer Research.

[33]  B. Evers,et al.  PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. , 2010, Anticancer research.

[34]  Yan Shi,et al.  Coexpression of PDGFR-Alpha, PDGFR-Beta and VEGF as a Prognostic Factor in Patients with Hepatocellular Carcinoma , 2011, International Journal of Biological Markers.

[35]  J. Tenenbaum,et al.  A Melanoma Molecular Disease Model , 2011, PloS one.

[36]  J. Bruix,et al.  Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.

[37]  H. Lien,et al.  Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. , 2005, Cancer letters.

[38]  H. Huynh,et al.  Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma , 2009, Journal of cellular and molecular medicine.

[39]  F. Sommerer,et al.  Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.

[40]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[41]  A. Zhu.  Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. , 2012, Seminars in oncology.